GoAI
Get started
Arcadia Biosciences, Inc. logo

Arcadia Biosciences, Inc.

RKDA

NASDAQBasic MaterialsAgricultural Inputs

Open in GoAI

Previous close

$0.4576

−$0.0046 · -1.00%

Aug 21, 4:00 PM ET

RKDA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

44

Fair Value

Momentum

17

Strong Down

Sentiment

39

Bearish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products. Additionally, it is actively engaged in agricultural research and development, with a particular focus on improving wheat crops. The aim of these innovations is to enhance farmers' economic stability by boosting crop performance in the field, increasing their value for food and wellness applications, and expanding their potential for industrial uses. Established in 2002, the company's main office is located in Davis, California.

Industry
Agricultural Inputs
Sector
Basic Materials
Headquarters
US
CEO
Thomas J. Schaefer
Listed since
May 15, 2015
Employees
8

Market position

Day range

Current $0.4576

52-week range

Current $0.4576

Open
$0.4695
Previous close
$0.4622
Volume
40.55K
0.02× average
Average volume
2.19M
Average daily volume
Market cap
708.05K USD
Beta
0.55
Market reference 1
50-day average
$0.6791
-32.62% below average
200-day average
$1.7365
-73.65% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.45M USD
P/E (TTM)
-0.08×
P/B (TTM)
1.84×
P/S (TTM)
0.15×
EV / EBITDA
-1.07×
Earnings yield
-86.35%
Free cash flow yield
-174.95%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
34.58%
Operating margin
-85.52%
Net margin
-234.53%
Return on equity
-56.50%
Return on assets
-35.73%
Return on invested capital
-222.75%

Financial health

Debt / equity
0×
Current ratio
3.09×
Altman Z-score
-73.85
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends109%-121%-351%-581%Gross margin, FY2021: -28.44%Gross margin, FY2022: 17.75%Gross margin, FY2023: 51.19%Gross margin, FY2024: 41.27%Gross margin, FY2025: 36.23%Operating margin, FY2021: -523.98%Operating margin, FY2022: -188.82%Operating margin, FY2023: -137.00%Operating margin, FY2024: -72.31%Operating margin, FY2025: -205.74%Net margin, FY2021: -216.22%Net margin, FY2022: -207.28%Net margin, FY2023: -313.90%Net margin, FY2024: -139.50%Net margin, FY2025: -48.15%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -28.44%. Gross margin FY2022 17.75%. Gross margin FY2023 51.19%. Gross margin FY2024 41.27%. Gross margin FY2025 36.23%. Operating margin FY2021 -523.98%. Operating margin FY2022 -188.82%. Operating margin FY2023 -137.00%. Operating margin FY2024 -72.31%. Operating margin FY2025 -205.74%. Net margin FY2021 -216.22%. Net margin FY2022 -207.28%. Net margin FY2023 -313.90%. Net margin FY2024 -139.50%. Net margin FY2025 -48.15%.

Income trends

Revenue

4.86M USD-3.71%

Operating income

−10M USD-173.99%

Net income

−2.34M USD+66.77%
Income trends across reported periods11.71M USD−5.47M USD−22.64M USD−39.82M USDRevenue, FY2021: 6.78M USDRevenue, FY2022: 7.42M USDRevenue, FY2023: 4.45M USDRevenue, FY2024: 5.05M USDRevenue, FY2025: 4.86M USDOperating income, FY2021: −35.53M USDOperating income, FY2022: −14.01M USDOperating income, FY2023: −6.1M USDOperating income, FY2024: −3.65M USDOperating income, FY2025: −10M USDNet income, FY2021: −14.66M USDNet income, FY2022: −15.38M USDNet income, FY2023: −13.98M USDNet income, FY2024: −7.04M USDNet income, FY2025: −2.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 6.78M USD. Revenue FY2022 7.42M USD. Revenue FY2023 4.45M USD. Revenue FY2024 5.05M USD. Revenue FY2025 4.86M USD. Operating income FY2021 −35.53M USD. Operating income FY2022 −14.01M USD. Operating income FY2023 −6.1M USD. Operating income FY2024 −3.65M USD. Operating income FY2025 −10M USD. Net income FY2021 −14.66M USD. Net income FY2022 −15.38M USD. Net income FY2023 −13.98M USD. Net income FY2024 −7.04M USD. Net income FY2025 −2.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.86M USD5.05M USD4.45M USD7.42M USD6.78M USD
Cost of goods sold3.1M USD2.96M USD2.17M USD6.1M USD8.71M USD
Gross profit1.76M USD2.08M USD2.28M USD1.32M USD−1.93M USD
Research and development9K USD53K USD64K USD1.51M USD3.89M USD
Selling, general, and administrative7M USD9.64M USD8.23M USD15.04M USD22.94M USD
Operating expenses11.76M USD5.73M USD8.38M USD15.32M USD33.6M USD
Interest income221K USD782K USD695K USD289K USD—
Interest expense————20K USD
Depreciation and amortization32K USD113K USD287K USD479K USD1.05M USD
Operating income−10M USD−3.65M USD−6.1M USD−14.01M USD−35.53M USD
Net income−2.34M USD−7.04M USD−13.98M USD−15.38M USD−14.66M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-10.82%
11 comparable reports
Latest EPS result
-2.09
Estimate -0.56 · Miss by 273.21%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.250.56-1.14-2.83Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -2.48, estimate -0.89, surprise -178.65%, Miss. Q2 2025, reported May 8, 2025: actual 1.9, estimate -0.98, surprise +293.88%, Beat. Q3 2025, reported Aug 14, 2025: actual 0.02, estimate -0.79, surprise +102.53%, Beat. Q4 2025, reported Nov 7, 2025: actual 0.62, estimate -0.54, surprise +214.81%, Beat. Q1 2026, reported Mar 26, 2026: actual -0.98, estimate -0.66, surprise -48.48%, Miss. Q2 2026, reported May 14, 2026: actual -2.11, estimate -0.8, surprise -163.75%, Miss. Q3 2026, reported Aug 13, 2026: actual -2.09, estimate -0.56, surprise -273.21%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.46, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.52M1.94M1.36M781.08KQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 1.22M USD, estimate 1.15M USD, surprise +5.74%, Beat. Q2 2025, reported May 8, 2025: actual 1.2M USD, estimate 1.3M USD, surprise -7.69%, Miss. Q3 2025, reported Aug 14, 2025: actual 1.46M USD, estimate 2.2M USD, surprise -33.86%, Miss. Q4 2025, reported Nov 7, 2025: actual 1.3M USD, estimate 1.9M USD, surprise -31.47%, Miss. Q1 2026, reported Mar 26, 2026: actual 901K USD, estimate 1.4M USD, surprise -35.64%, Miss. Q2 2026, reported May 14, 2026: actual 1.1M USD, estimate 1.6M USD, surprise -31.25%, Miss. Q3 2026, reported Aug 13, 2026: actual 1.44M USD, estimate 1.9M USD, surprise -24.05%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate 2.4M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$6.00

1211.19% upside
Past 12 months12-month forecastHigh $6.00Average $6.00Low $6.00

Rating distribution

5 ratings
Strong buy00%
Buy480%
Hold120%
Sell00%
Strong sell00%

Recent analyst actions

1 institution

RKDA news

globenewswire.com

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

– Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash – – July monthly Zola ® sales top $740K; exceed $1…

Read source
defenseworld.net

Arcadia Biosciences (NASDAQ:RKDA) versus Diageo (NYSE:DEO) Critical Comparison

Diageo (NYSE: DEO - Get Free Report) and Arcadia Biosciences (NASDAQ: RKDA - Get Free Report) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength…

Read source
globenewswire.com

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement…

Read source
globenewswire.com

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement…

Read source
globenewswire.com

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the…

Read source
globenewswire.com

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for…

Read source

Corporate actions

Corporate action history

Stock split

Effective Mar 1, 2023

1:40

Stock split

Effective Jan 24, 2018

1:20

RKDA peers

Linde plc logo

LIN

Linde plc

$487.57

+1.30%

Steel Dynamics, Inc. logo

STLD

Steel Dynamics, Inc.

$228.68

+4.42%

Royal Gold, Inc. logo

RGLD

Royal Gold, Inc.

$259.01

+2.64%

Solstice Advanced Materials Inc. logo

SOLS

Solstice Advanced Materials Inc.

$56.16

-0.81%

SSR Mining Inc. logo

SSRM

SSR Mining Inc.

$37.77

+2.55%

Aura Minerals logo

AUGO

Aura Minerals

$87.26

+0.66%

ETFs holding RKDA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.03K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research RKDA

research.disclaimer